AI and Data in Pharmacy Benefit Management: In Conversation with Renzo Luzzatti

Pharmacy benefit management is built on complex decisions around cost, care, and access. As data volumes grow and workflows become more intricate, traditional approaches are struggling to keep pace.

AI is beginning to change that. From streamlining operations to improving how decisions are evaluated, it offers a way to bring more structure, speed, and consistency into the system.

But its impact depends on more than just adoption. It requires strong healthcare data governance foundations, integrated workflows, and clearly defined processes.

At Radixweb, we work with organizations to design and implement AI-driven systems that operate within real-world constraints, where accuracy, accountability, and scalability are critical.

To explore how these shifts are playing out specifically in the PBM landscape, we spoke with Renzo Luzzatti, President and CEO of US-Rx Care. With over three decades of experience in pharmacy risk management, he shares his perspective on industry challenges, the role of technology, and what it takes to improve outcomes at scale.

About the Expert

Renzo Luzzatti is the President & CEO of US-Rx Care, where he pioneered the nation’s first fiduciary Pharmacy Benefit Manager to restore transparency, accountability, and client-first ethics to the PBM industry. With more than 30 years of leadership in pharmacy risk management and benefit optimization, he has guided employers, health plans, and policymakers toward sustainable models that deliver better outcomes at dramatically lower costs.

In Conversation with Renzo Luzzatti

How is technology, especially, AI transforming PBM operations?

Where technology has come into play in PBM operations are three key areas:

• The use of AI in multiple ways to streamline otherwise time-consuming or manual processes
• Mobile apps that assist patients in navigating and getting the most out of their pharmacy benefit. The most important advancement is access to information delivered to patients via mobile technology. Valuable information can include things like lower cost alternatives to discuss with the doctor, lower cost pharmacy options other than the one electronically selected by the doctor, formulary status, including prior authorization status and navigation, coupon options to lower out of pocket cost, and more.
• Advances in prescriber communications providing more useful and actionable information regarding plan formulary options, patient costs, and medication costs, again to facilitate better decision-making at the point of prescribing.

Can you share a case where data-driven insights significantly improved pharmacy operations or patient outcomes?

Data, of course, is royalty in healthcare. Better data facilitates better decision-making for all. In this realm, we believe the PBM industry has taken a step back when it comes to the evaluation of high-cost medications that require prior authorization for approval. The industry has moved largely to electronic PA processing based on responses from prescribers to scripted questions and drop-down menus without any validation or interrogation for accuracy. Often, it may not be the prescriber who is submitting the information. This approach leads to exceptionally high approval rates, with a high error rate, meaning medications are approved for non-covered uses, incorrect doses, or outside common best practices.

The solution here is to rely on the patient’s medical record to get a full picture of the patient, the course of the disease, medications tried and failed in the past, diagnostic test results, concomitant conditions, and more. All of these factors factor into appropriate therapy selection to ensure the best option is selected for the patient.

How do you see the role of ethics and fiduciary responsibility evolving in healthcare and pharmacy management?

The main problem with the PBM industry today is a lack of fiduciary accountability. That includes traditional PBMs and the new wave of transparent PBMs as well. In simplest terms, PBMs have evolved into entities that sell prescription medications to individuals enrolled in health plans at a profit. They have devised dozens of ways to profit from medications they process, most of which are not transparent to the payer.

The best way for plan sponsors to gain control of their pharmacy costs is to eliminate all conflicts of interest in their PBM relationship. The easiest way to do that is to demand that the PBM, the entity responsible for administering and being a good financial steward of the pharmacy benefit, take on fiduciary responsibility subject to the same legal obligations of the plan sponsors themselves.

How can advanced analytics and AI help PBMs better manage costs while maintaining patient care quality?

AI is a significant efficiency booster in many ways that has captured significant attention across industries. PBMs are looking at AI to automate any number of functions from call center support, to prior authorization reviews, to member and prescriber navigation of health plan benefits. When it comes to managing pharmacy benefits, care is needed to ensure that AI efficiencies do not come at the expense of member experience or quality of care. To date, AI use to evaluate a medical record is not quite ready for prime time to replace human review and insight. Any improvements there that can shorten review time would be welcome, though complete replacement of human review and insight is likely to be years away.

Looking forward, what is your vision for the PBM industry, and how can technology and digital tools support that vision?

We are beyond a breaking point when it comes to spending on pharmaceuticals in the United States, and plan sponsors are bearing the lion’s share of that cost. The stakes and cost of continuing to do things the same old way are simply too high. The cost of medications, in particular, and healthcare as a whole, is taking a toll on American industry and negatively impacting our global competitiveness as a society, along with diminished quality of life when individuals cannot afford needed medication therapy.

So many employers who have already adopted our fiduciary PBM model have seen their health plan and member costs drop by 30%-50% or more in 12 months or less. However, they still represent just a fraction of the market. Pharmacy benefit waste and overspend is arguably the simplest and quickest part of the health care equation to fix with minimal to no disruption to plan enrollees. Doing so requires looking at new PBM models like US-Rx Care’s fiduciary approach that is free of conflicts of interest and committed to always putting the health plan and enrollees first.

Radixweb’s Perspective on AI, Transparency, and PBM Transformation

Renzo Luzzatti’s insights highlight a critical reality: the biggest challenges in pharmacy benefit management are not just structural, they are systemic. Issues like lack of transparency, misaligned incentives, and fragmented data cannot be solved through incremental changes alone.From a technology standpoint, this is where AI and advanced data systems can play a meaningful role, but only when implemented with the right intent and foundation.For PBMs and healthcare organizations, the opportunity lies in building systems that:● Bring together clinical, financial, and operational data into a unified view● Enable more accurate, context-aware decision-making rather than isolated automation● Support transparency through traceable, auditable workflows ● Balance efficiency gains with clinical oversight and accountabilityAI, in this context, is not just about automation. It is about enabling better decisions at scale, reducing inefficiencies, and creating systems that are aligned with patient outcomes and cost responsibility.As the role of AI in the broader healthcare industry continues to evolve, with market valuation expected to reach $45.2 billion by 2026, organizations that invest in strong data foundations, integrated platforms, and responsible AI frameworks will be better positioned to navigate complexity while delivering measurable value.At Radixweb, we see this shift clearly across healthcare systems adopting AI. The focus is no longer on isolated use cases, but on building connected, scalable ecosystems where technology supports both operational efficiency and ethical accountability. If that’s something you are also exploring next, schedule a no-cost strategy session with our AI consultants today.